A panelist discusses the evolving role of prophylactic tocilizumab in reducing cytokine release syndrome during bispecific antibody therapy, enabling outpatient treatment and improving patient ...
Using the best medication available in the frontline setting of RCC leads to optimal results. David Braun, MD, of the Yale School of Medicine explores the strategic tension between immediate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results